Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating on Ultragenyx Pharma (NASDAQ: RARE).The analyst comments "Bottom Line: Ionis (IONS ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE